ACLARIS THERAPEUTICS INC (ACRS) Stock News

Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes

Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes...

Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference

Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference ...

Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052

Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052...

Aclaris Therapeutics to Participate in Two June Healthcare Conferences

WAYNE, Pa., May 28, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing...

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Mentions: SPRO RGC WORX SNTI ...

This Arista Networks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Mentions: ALKS MRVL ANET NPCE

Aclaris Therapeutics Announces $80 Million Private Placement

Aclaris Therapeutics Announces $80 Million Private Placement...

Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series

Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series...

Aclaris Therapeutics (ACRS) Reports Q1 Loss, Misses Revenue Estimates

Aclaris (ACRS) delivered earnings and revenue surprises of 29.41% and 65.15%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Mentions: PSTV

Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update...

Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer

Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer ....

Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052, Enabling Advancement of its Novel Bispecific Anti-TSLP/IL-4R Investigational Antibody

Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052...

Aclaris Therapeutics to Participate in Two March Healthcare Conferences

Aclaris Therapeutics to Participate in Two March Healthcare Conferences...

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update...

New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3

New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3...

Aclaris Therapeutics Announces Formation of New Scientific Advisory Board

Aclaris Therapeutics announces formation of new scientific advisory board...

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)...

Pony AI, Thermo Fisher initiated: Wall Street's top analyst calls

Pony AI, Thermo Fisher initiated: Wall Street's top analyst calls

Mentions: RJF WY PCH GCMG

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)...

Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference ...

Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets

Biosion receives over $40 million cash payment as upfront license fee and reimbursement for certain development costs & drug product materials, and 19.9%...

Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline

Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline...

Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update ...

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the...

Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference...

Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update...

Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million

Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million...